Nostrum Announces The Successful Completion Of Early Proof Of Concept Study For Its Novel Clot Busting Therapeutic Protein

Nostrum Announces The Successful Completion Of Early Proof Of Concept Study For Its Novel Clot Busting Therapeutic Protein: "Nostrum, a privately-held company based in Edison, New Jersey, announced that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum’s Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum’s license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006."

Click here for more links at lancerlord.